Cridanimod (IM; 1-6 mg; twice a week) has a significantly longer survival time. Cridanimod significant increases in IFNα and -β in cridanimod-treated mice in a dose-dependent manner. Animal Model: Athymic mice with hec50co cells Dosage: 1, 3, 6 mg Administration: IM; twice a week Result: Had a significantly longer survival time.